Press Release
Vadodara, 24th October, 2019
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th September 2019.
Financial Highlights
· Net Sales for the quarter up 10% to Rs 1241 crores from Rs. 1127 crores last year.
· Net Profit for the quarter up 23% to Rs 246 crores from Rs 200 crores last year.
· Net sales for H-1 FY20 up 10% to Rs 2190 crores against Rs 1990 crores last year.
· Net profit for H-1 FY20 up 27% to Rs 370 crores from Rs 291 Crores last year.
Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said
“It was a good quarter for the company led by growth in the US market and the API business. We launched 7 products in the US market in Q2. We continue to invest in R&D to build up a product pipeline.”
Operational Highlights
International Business
· International formulations grew 10% to Rs 646 crores in the quarter and 17% to Rs 1099 crores for H-1.
· US Generics grew 25% to Rs 539 crores in the quarter and 35% to Rs 884 Crores for H-1.
· 6 ANDA approvals received during the quarter; 102 Cumulative ANDA approvals.
· 5 ANDA filings during the quarter; Cumulative ANDA filings at 170.
· EIR’s for all the plants in place.
India Formulations Business
· India formulations business for the quarter was Rs 391 crores as against Rs 385 crores for the last year.
API Business
· API business grew 31% to Rs 204 crores as against Rs 155 crores for the last year.
· 2 DMF were filed in the quarter and total tally of DMF stand at 102.
Summary of Total Revenue is as under:
(Rs in Crores)
|
Particulars
|
Q2 FY20
|
Q2 FY19
|
% Change
|
H1 FY20
|
H1 FY19
|
% Change
|
|
Formulation
|
||||||
|
USA
|
539
|
431
|
25%
|
884
|
656
|
35%
|
|
Ex-USA
|
107
|
156
|
-31%
|
215
|
283
|
-24%
|
|
India
|
391
|
385
|
2%
|
715
|
716
|
0%
|
|
API
|
204
|
155
|
31%
|
376
|
335
|
12%
|
|
Total
|
1241
|
1127
|
10%
|
2190
|
1990
|
10%
|
The Profit break-up is as under:
(Rs in Crores)
|
Particulars
|
Q2 FY20
|
Q2 FY19
|
% Change
|
H1 FY20
|
H1 FY19
|
% Change
|
|
EBITDA Pre R&D
|
505
|
443
|
14%
|
869
|
710
|
22%
|
|
EBITDA Pre R&D %
|
41%
|
39%
|
40%
|
36%
|
||
|
EBITDA Post R&D
|
342
|
305
|
12%
|
575
|
456
|
26%
|
|
EBITDA Post R&D %
|
28%
|
27%
|
26%
|
23%
|
||
|
Profit Before Tax before exceptional items
|
299
|
270
|
10%
|
491
|
392
|
25%
|
|
Net Profit after Tax
|
246
|
200
|
23%
|
370
|
291
|
27%
|
Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic’s state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic’s brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.
Information about the company can be found at www.alembicpharmaceuticals.com; (reuters: ALEM.NS) (bloomberg: ALPM) (nse: APLLTD) (bse: 533573)
